Skip to main content
. 2022 May 6;14(7):e15203. doi: 10.15252/emmm.202115203

Figure EV1. Efficacy of DHODH inhibition in the MN murine AML model.

Figure EV1

  1. Schematic of MN model.
  2. Body weight of MN tumor‐bearing mice treated with AG636. Gray bars denote treatment. Dotted line defines zero percent weight loss.
  3. Number of recipient‐derived myeloid cells (CD45.1+CD11b+Ly6G+) in the peripheral blood of AG636‐ or doxycycline‐treated recipients at the conclusion of therapy and after 4 weeks (n = 8–10 mice/group).
  4. Representative FACS plots of the bone marrow from a mouse with no detectable disease (M#13) and a relapsed mouse (M#15).
  5. Kaplan–Meier survival curve of secondary recipients transplanted with leukemic cells from the relapsed donor (M#15) or a control donor from the vehicle group (M#30). Gray bars denote treatment (n = 4 mice/group, median survival is 21.5 for vehicle‐treated M#30, 42 for AG636‐treated M#30, 23 for vehicle‐treated M#15, and not reached for AG636‐treated M#15, the P value was calculated by log‐rank test).
  6. Number of MN cells in the spleen and peripheral blood quantified by flow cytometry (n = 3–6 mice/group).
  7. Number of LSCs (CD11blowcKithighFcgR+) and differentiated leukemic cells (CD182+Ly6G+) in the bone marrow (n = 3–6 mice/group).

Data information: data in F‐G are presented as mean ± SD; P values were calculated using a one‐tailed Student’s unpaired t‐test. *P < 0.05, **P < 0.01, Dox—doxycycline.

Source data are available online for this figure.